Agentic AI is the term of 2025 in clinical operations. Every EDC vendor, every CRO, and every AI platform targeting pharma has added it to their slide deck. Most uses of the term mean approximately nothing — a synonym for "AI feature," deployed to convey capability without having to describe it precisely.
The distinction matters because agentic AI, precisely defined, has real implications for clinical trial compliance, regulatory submissions, and the role of your data management team. Understanding what it is, what it is not, and what it requires from a compliance architecture helps you ask the right questions when evaluating platforms that claim it.
A precise definition
An agentic AI system is one where an AI model takes a sequence of actions — using tools, making decisions, producing outputs — in order to complete a multi-step task, without a human directing each individual step. The defining characteristic is that the AI orchestrates its own workflow rather than responding to a single prompt and stopping.
In a clinical trial data management context, an agentic pipeline might: read a protocol PDF, extract the study design as a structured USDM object, generate a draft CRF specification, map each CRF field to an SDTM variable with confidence scores and rationale, produce a DMP draft referencing the CRF and mapping, and generate Define-XML — all as a connected sequence of automated steps, each building on the previous. No human intervention between steps; a human review at the output of each.
This is categorically different from a chatbot that answers questions about clinical trials, or an AI-assisted form that suggests autofill values. Those are AI-assisted tools. An agentic pipeline is a system where the AI is executing a workflow, not responding to individual queries.
The spectrum from assisted to agentic
It is useful to think about a spectrum rather than a binary distinction:
AI-assisted tools respond to individual user actions. You click a button, the AI suggests a value, you accept or modify. The human drives the workflow; the AI provides suggestions at specific decision points. Most "AI features" in existing EDC and data management tools fall here.
AI-orchestrated workflows execute multi-step tasks with the human setting the inputs and reviewing the outputs. The AI handles the intermediate steps — document parsing, extraction, transformation, mapping — without requiring human input at each stage. The human's role shifts from directing each step to reviewing the pipeline's output and approving before it is committed.
Autonomous agents operate without human oversight at the point of execution, committing outputs directly to systems of record. In regulated clinical trials, this category is currently inappropriate for any output that influences a clinical data artifact. The regulatory requirement for human review before clinical records are created or modified is not satisfied by autonomous agents operating without an approval gate.
The value of agentic AI in clinical trials lives in the middle category: AI-orchestrated workflows with human review at decision points. Not autonomous. Not fully manual. The agent does the translation work; the qualified human does the review.
What agentic AI can do in clinical trial data management today
The use cases where agentic pipelines deliver reliable, regulation-appropriate value are well-defined:
Protocol parsing and structuring. Extracting the structured information from a protocol narrative — endpoints, eligibility criteria, visit schedules, planned assessments — is exactly the kind of multi-step, document-intensive task that agentic pipelines handle well. The output is a USDM-structured protocol object that downstream agents and downstream humans can both work with.
SDTM mapping documentation. Given a structured protocol and a CRF specification, generating an initial SDTM mapping document — with variable-level mappings, confidence scores, controlled terminology assignments, and rationale — is a high-value agentic use case. The output requires expert review; the generation does not require expert production.
Define-XML generation. Given a confirmed SDTM mapping, generating the corresponding Define-XML v2.1 metadata document is an agentic task with well-specified rules and a clear validation criterion (passing Pinnacle 21). This is not a task that requires clinical judgment; it is a structured encoding task that agents perform accurately and consistently.
DMP drafting. The Data Management Plan references the CRF, the edit check specifications, the query management procedures, and the SDTM mapping. Given those source documents, drafting the DMP is a template-filling and cross-referencing exercise that an agent can perform with human review of the output.
What agentic AI cannot do in regulated trials — and should not be asked to
The failure modes of agentic AI in clinical trials cluster around judgment, novelty, and accountability.
Clinical judgment calls. Deciding whether an adverse event is related to study drug requires clinical expertise, knowledge of the patient's history, and professional accountability. An agent can prepare the materials for that decision and structure the options clearly. The decision belongs to the clinician.
Sponsor-specific conventions. Agentic pipelines trained on CDISC documentation know the standard. They do not know your organization's undocumented SDTM conventions, your historical SUPP-- variable naming patterns, or your sponsor-specific domain extensions. These must be reviewed by a DM lead who knows the institutional context.
Novel domains and emerging standards. For data types not well-represented in the training corpus — wearable device data, novel biomarkers, new patient-reported outcome instruments — agentic pipeline outputs carry lower confidence and require more intensive human review. The agent should flag these explicitly; a compliant pipeline should not auto-commit low-confidence outputs.
Final accountability. In a regulated trial, every data artifact carries an attributed approver who is professionally accountable for its accuracy. An agentic pipeline can produce the artifact. It cannot sign off on it. The approver is always a qualified person.
How to evaluate a platform that claims agentic AI
Ask four questions. First: what does the agent actually do, step by step? "Agentic AI" is not a specification. Ask for the task decomposition — what inputs does the agent receive, what outputs does it produce, what tools does it use between input and output?
Second: where is the human in the loop? Every compliant agentic platform has defined approval gates where human review occurs before outputs are committed to regulated records. Ask where those gates are, whether they are configurable, and whether the audit trail distinguishes between auto-committed and human-approved outputs.
Third: what is logged? The audit trail for an agentic pipeline must capture agent-level operations — which agent made each inference call, with what model version, on what input, producing what output, at what time. If the audit trail only captures human interactions, the agent's contribution to the record is invisible to an inspector.
Fourth: what is the validation package? Agentic AI systems used to produce SDTM, ADaM, or Define-XML require validation documentation specific to that use case. Ask for it.
The word "agentic" should be the beginning of a technical conversation, not the end of one. The platforms that use it precisely, can demonstrate it specifically, and have built the compliance architecture around it are the ones worth evaluating seriously.